Key clinical point: Physicians who treat STIs in their offices should maintain stocks of the appropriate injectable drugs.
Major finding: Among physicians treating STIs in their offices, 77.9% did not have penicillin G benzathine available on- site, and 56.1% did not have ceftriaxone.
Study details: Survey results from the 2016 Physician Induction File of the National Ambulatory Medical Care Survey.
Disclosures: The authors are all employees of the CDC and did not provide other disclosures.
Pearson WS et al. Emerg Infect Dis. 2019. doi: 10.3201/eid2511.190764.